The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some available weight loss treatments, retatrutide appears to offer a more substantial reduction in body mass and enhance metabolic function